



7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
--	---	---	---	---

Title	Amount or Number of Shares
-------	----------------------------


**Explanation of Responses:**  
(1) The transaction date was fixed at the effective closing of the Merger between StemSource Inc. and MacroPore Biosurgery, Inc.  
(2) Mr. Bisimis acquired the shares by virtue of the merger exchange of 19,987 preferred shares of StemSource Inc. in return for 10,684 shares of MacroPore Biosurgery, Inc. The MacroPore shares were valued at \$4.15 each on the date of closing.  
(3) The number of securities beneficially owned at the date for which this statement was prepared does not include any adjustment for transactions which occurred subsequently but were reported prior to this filing. Taking into account this subsequent filing the total number of shares beneficially owned as of the report on December 3, 2002 is 80,302.

/s/ Ari Bisimis  **Signature of Reporting Person	01/30/03  Date
--	----------------------

**Reminder:** Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v)
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**Note:** File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.